BCR-ABL: The molecular mastermind behind chronic myeloid leukemia

This publication has 140 references indexed in Scilit:

• Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
  American Journal of Hematology, 2024
• Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance
  Pharmacology Research & Perspectives, 2024
• Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia
  American Journal of Hematology, 2022
• Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review
  Medical Oncology, 2021
• Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes
  American Journal of Hematology, 2020
• The topological organization of chromosomes 9 and 22 in cell nuclei has a determinative role in the induction of t(9,22) translocations and in the pathogenesis of t(9,22) leukemias
  Chromosoma, 1999
• The cytostatic function of c‐Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
  The EMBO Journal, 1996
• Chronic myelogenous leukemia and exposure to ionizing radiation — a retrospective study of 443 patients
  Annals of Hematology, 1995
• An actin‐binding function contributes to transformation by the Bcr‐Abl oncoprotein of Philadelphia chromosome‐positive human leukemias.
  The EMBO Journal, 1993
• An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
  Cell, 1984